PerkinElmer acquires German firm

PerkinElmer has acquired Germany's chemagen Biopolymer-Technologie, a key player in the field of automated nucleic acid isolation. The purchase is part of PerkinElmer's strategy to advance its offerings to the molecular diagnostics and research markets.

"The addition of chemagen's complementary products to PerkinElmer's portfolio will provide the Company with robust platforms and solutions to meet the needs of the rapidly evolving molecular diagnostics market," Daniel Marshak, chief scientific officer and president, Emerging Diagnostics, says in a statement. "The hardware and reagent capabilities brought by chemagen include a total solution in nucleic acid sample preparation, with automation-enabling features that can power high throughput applications in research, screening, and diagnostics."

Chemagen was founded in December 1997, and its scientific foundations were laid at the RWTH Technical University of Aachen. No financial details related to the deal are being disclosed.

- get the PerkinElmer release

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.